A recent myeloma meeting in Rostock (Saturday, 15.th of March 2025) did indeed show OSHO registry data (https://osho-services.de/services/klinische-studien-und-register) of different PI-, IMID-, CD38-ab-treatment sequences within this registry, demonstrating that IRd was given both upfront (2.−4th line), but also in later lines (≥ 5 th-14.th line; personal communication Profs. The gene discussed is CD38; the disease is plasma cell myeloma.